| Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.J Am Acad Child Adolesc Psychiatry | PMID 35577034无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.Emerg Microbes Infect | PMID 35686572PMC9347473 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1).Br J Dermatol | PMID 35791755PMC10087045 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.Emerg Microbes Infect | PMID 35792746PMC9331225 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera® ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial.Hematol Oncol | PMID 35858181无 PMCID | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.J Diabetes Investig | PMID 35861630PMC9720226 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.Am J Obstet Gynecol | PMID 35863457无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Participant characteristics and safety outcomes of peanut oral immunotherapy in the RAMSES and ARC011 trials.Ann Allergy Asthma Immunol | PMID 35973655无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effectiveness of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection of the Needle Tip in Decreasing Infectious Complications After Transrectal Prostate Biopsy: A Randomized Controlled Trial.J Urol | PMID 36006040无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Obinutuzumab as consolidation after chemo-immunotherapy: Results of the UK National Cancer Research Institute phase II/III GALACTIC trial.Br J Haematol | PMID 36017875PMC9805170 | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial.Lancet Infect Dis | PMID 36037823无 PMCID | 2022-Dec | 0.85 | The study is a randomized Phase III trial of a drug-containing vaccine intervention (HPV 16/18 vaccine) reporting final efficacy results for human cancer prevention. However, the primary efficacy endpoints (high-grade genital lesions, persistent infection) are categorical outcomes (vaccine efficacy percentages), not the required time-to-event endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). | 待处理 |
| Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.Clin Lung Cancer | PMID 36038416无 PMCID | 2022-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).Cancer Sci | PMID 36062851PMC9746048 | 2022-Dec | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.Lancet Infect Dis | PMID 36075233PMC9444237 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety of tralokinumab in adult patients with moderate-to-severe atopic dermatitis: pooled analysis of five randomized, double-blind, placebo-controlled phase II and phase III trials.Br J Dermatol | PMID 36082590PMC10091996 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Levoketoconazole in the treatment of patients with endogenous Cushing's syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS).Pituitary | PMID 36085339PMC9675660 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase III, Randomized, Controlled Trial Comparing Open Versus Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma.Ann Surg Oncol | PMID 36085388PMC10673682 | 2022-Dec | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Respir Med | PMID 36087611PMC9451499 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.Ann Rheum Dis | PMID 36109142PMC9664111 | 2022-Dec | 0.90 | The study is a Phase III randomized controlled trial in rheumatoid arthritis, not oncology. The primary and key secondary endpoints are ACR20 response and DAS28(CRP)<3.2, which are clinical response/proportion-based outcomes, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). | 待处理 |
| Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Infect Dis | PMID 36113538PMC9639796 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC) trial.Hypertens Res | PMID 36123398无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Determination of a clinically effective evobrutinib dose: Exposure-response analyses of a phase II relapsing multiple sclerosis study.Clin Transl Sci | PMID 36126241PMC9747124 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study.J Thromb Haemost | PMID 36138517PMC9827931 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Perspectives on rosacea patient characteristics and quality of life using baseline data from a phase 3 clinical study conducted in Japan.J Dermatol | PMID 36177741PMC10092295 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial.Lancet Gastroenterol Hepatol | PMID 36183738无 PMCID | 2022-Dec | 0.95 | The record describes a randomized, Phase 3 trial of drug interventions (TETA4 vs. penicillamine) for Wilson disease, which is not a human malignant neoplasm. The primary efficacy endpoint is serum non-caeruloplasmin-bound copper (NCC), a continuous biomarker, not a time-to-event endpoint (e.g., OS, PFS, DFS). Therefore, it is excluded from the oncology Kaplan-Meier digitization cohort. | 待处理 |
| Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference - Substudy of the randomised phase III GAIN-2 study.Breast | PMID 36223695PMC9563210 | 2022-Dec | 0.95 | This is a randomized Phase III trial of trastuzumab in early breast cancer, but the study's primary endpoints are pharmacokinetics, patient preference, and safety. It does not report a time-to-event efficacy endpoint like overall survival or disease-free survival. | 待处理 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.Ann Oncol | PMID 36228963PMC10207856 | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study.Gynecol Oncol | PMID 36244828无 PMCID | 2022-Dec | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Volume matters: Breast induration is associated with irradiated breast volume in the Danish Breast Cancer Group phase III randomized Partial Breast Irradiation trial.Radiother Oncol | PMID 36265685无 PMCID | 2022-Dec | 0.80 | The study meets oncology, human, randomized, and Phase III criteria, but it does not meet the required drug intervention or time-to-event efficacy endpoint criteria. The intervention is a non-drug radiotherapy technique, and the primary reported outcome is a toxicity measure (breast induration), not a time-to-event efficacy endpoint. | 待处理 |
| Characterization of exposure-response relationships of ipatasertib in patients with metastatic castration-resistant prostate cancer in the IPATential150 study.Cancer Chemother Pharmacol | PMID 36305957PMC9637074 | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia: Phase 3, Multinational Open-Label Study.Arterioscler Thromb Vasc Biol | PMID 36325897PMC9750107 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Nivolumab plus ipilimumab plus cabozantinib triplet combination for patients with previously untreated advanced renal cell carcinoma: Results from a discontinued arm of the phase III CheckMate 9ER trial.Eur J Cancer | PMID 36327527PMC9750497 | 2022-Dec | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3).Cancer Commun (Lond) | PMID 36336841PMC9759762 | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period.Lancet Diabetes Endocrinol | PMID 36356613PMC9847480 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial.Nat Microbiol | PMID 36357712PMC10166187 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial.Eur J Cancer | PMID 36368252无 PMCID | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial.EBioMedicine | PMID 36370634PMC9664402 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.Lancet Oncol | PMID 36370716无 PMCID | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial.Psychiatry Res | PMID 36375329无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients.CNS Drugs | PMID 36385453无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial.Lancet Neurol | PMID 36402160无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer.Lung Cancer | PMID 36410210无 PMCID | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Multiple sclerosis clinical decision support system based on projection to reference datasets.Ann Clin Transl Neurol | PMID 36412095PMC9735373 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Importance of IL-6 inhibition in prevention and treatment of antibody-mediated rejection in kidney allografts.Am J Transplant | PMID 36453709无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.ESMO Open | PMID 36455504PMC9808443 | 2022-Dec | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix® 30 in Type 2 diabetes patients.J Comp Eff Res | PMID 36511777无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Yogliptin monotherapy in type 2 diabetes: A 12-week randomized, double-blind, placebo-controlled phase II study.J Diabetes | PMID 36515221PMC9789391 | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| [Advanced Medical Care].Gan To Kagaku Ryoho | PMID 36539239无 PMCID | 2022-Dec | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| MPFF 1000 mg chewable once daily vs. MPFF 500 mg twice daily in chronic venous disease: the double-blind, randomized, non-inferiority CHEWY trial.Int Angiol | PMID 36598370无 PMCID | 2022-Dec | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of darolutamide in Black/African-American patients from the phase III ARAMIS study.Future Oncol | PMID 36753353无 PMCID | 2022-Dec | 0.80 | The record describes a subgroup analysis of a Phase III randomized trial (ARAMIS) with drug intervention and time-to-event endpoints, but it is not the original primary result report of the trial. It is a secondary analysis focusing on a specific patient population, thus excluded per criteria. | 待处理 |